B. Riley reissued their hold rating on shares of Heska Corporation (NASDAQ:HSKA) in a report published on Friday, October 27th. They currently have a $96.50 target price on the medical research company’s stock.
“We expect Q3 results to be generally in line. We forecast revenue of $35.8 million and EPS of $0.40 versus consensus of $36.0 million and EPS of $0.41. We model revenue growth at 7.1%, reflecting ongoing momentum in core blood diagnostics within its Core Companion Animal Health offset by Other Vaccines, Pharmaceuticals and Products segment which pulled forward revenue last quarter (but expecting to finish off Q4 strong).”,” B. Riley’s analyst commented.
Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Heska Corporation from a buy rating to a hold rating in a research report on Sunday, July 16th. Aegis boosted their price target on shares of Heska Corporation from $114.50 to $129.50 and gave the stock a buy rating in a report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Heska Corporation from a hold rating to a buy rating and set a $109.00 price target on the stock in a report on Friday, August 4th. Benchmark Co. boosted their price target on shares of Heska Corporation from $106.00 to $120.00 and gave the stock a buy rating in a report on Thursday, August 3rd. Finally, Canaccord Genuity started coverage on shares of Heska Corporation in a report on Thursday, October 5th. They set a buy rating and a $115.00 price target on the stock. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $106.25.
Shares of Heska Corporation (HSKA) opened at $84.68 on Friday. Heska Corporation has a 52 week low of $62.06 and a 52 week high of $115.00. The firm has a market cap of $619.71, a price-to-earnings ratio of 44.79, a price-to-earnings-growth ratio of 2.28 and a beta of 0.83.
Heska Corporation (NASDAQ:HSKA) last posted its earnings results on Thursday, November 2nd. The medical research company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.37 by $0.03. The company had revenue of $31.40 million during the quarter, compared to the consensus estimate of $36.10 million. Heska Corporation had a net margin of 10.67% and a return on equity of 15.35%. The firm’s revenue for the quarter was down 6.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.45 earnings per share. equities analysts predict that Heska Corporation will post 2.03 EPS for the current fiscal year.
In other Heska Corporation news, CFO John Mcmahon sold 2,608 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $101.17, for a total value of $263,851.36. Following the transaction, the chief financial officer now directly owns 193 shares in the company, valued at $19,525.81. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Nancy Wisnewski sold 825 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $102.21, for a total transaction of $84,323.25. Following the completion of the transaction, the executive vice president now owns 38,114 shares in the company, valued at $3,895,631.94. The disclosure for this sale can be found here. 14.70% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of HSKA. Vanguard Group Inc. raised its position in shares of Heska Corporation by 47.0% in the first quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock valued at $36,807,000 after purchasing an additional 112,115 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Heska Corporation by 115.5% in the second quarter. Dimensional Fund Advisors LP now owns 120,174 shares of the medical research company’s stock valued at $12,266,000 after purchasing an additional 64,418 shares during the period. Geneva Advisors LLC raised its position in shares of Heska Corporation by 565.4% in the second quarter. Geneva Advisors LLC now owns 75,499 shares of the medical research company’s stock valued at $7,706,000 after purchasing an additional 64,153 shares during the period. Fred Alger Management Inc. raised its position in shares of Heska Corporation by 133.8% in the second quarter. Fred Alger Management Inc. now owns 97,229 shares of the medical research company’s stock valued at $9,924,000 after purchasing an additional 55,647 shares during the period. Finally, Principal Financial Group Inc. bought a new stake in shares of Heska Corporation in the first quarter valued at approximately $5,234,000. 78.58% of the stock is currently owned by institutional investors.
Heska Corporation Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.